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Abstract
Pain as an integral part of palliative care (PC) is often present at the end of the 
life. Today, many different analgesics from opioids and non- opioids origin are in 
use. The integration of their use is the most effective method for pain relief. The aim 
of this chapter is to discuss different therapeutic approaches to pain management 
in palliative care. Palliative care is being confronted between the expectations and 
the possibilities to provide an efficient relief from the symptoms, the pain and the 
stress. The possibility to use opioids for pain management, with all side effects, and 
non-addictive drugs as additional treatment, improves the quality and the duration 
of life for the patients in palliative care. Since the origin of the pain is different, the 
use of analgesic therapy should be individualized and adapted to the real need of 
every person. Finally, only a good organization and institutionalization of pallia-
tive care in the society could allow for better prevention of suffering at the end of 
the life.
Keywords: pain in palliative setting, multimodal analgesia, non-opioids, opioids, 
non-pharmacological therapy
1. Introduction
Pain is an integral part of palliative care (PC) and it is often present at the end 
of the life. Nowadays the understanding of “palliative care” has changed. The new 
approach in palliative care services integrates the latest knowledge and develop-
ments in medicine [1], providing care by specialized team of doctors for pain treat-
ment, surgery, interventions’ radiology, oncology, intern medicines and others. This 
integration of the knowledge from different specialties, offers in “hospices” a very 
high-quality care for the patients at the end of their life, where pain is managed by 
specialized professional teams [2]. This care is enriched with support in daily living, 
with psychological and spiritual care for patients and their families [3].
The philosophy of palliative care is to provide advanced care planning and 
support which helps the patient live an active, pain-free life, and the pain treatment 
is one of the most important curative methods during their habitation in a Hospice. 
Difficulties with impairments, such as sense of hearing, sight, and speech, often 
represent barriers in communication. Since the patients in palliative care are elderly 
persons, they are also burdened with the presence of some neurological diseases 
such as Alzheimer’s disease, dementia, or cognitive impairment, which is an 
additional problem in this context. Additionally, in patients with cardio-circulatory, 




Pain is very often present at the end of the life, but unfortunately the presence 
of pain in palliative care is underestimated. The reasons for that are multi-factorial. 
One of the reasons is a lack of communication and difficulties between the patients 
and the palliative care providers; the second is unrecognized and misunderstood 
presence of pain; the third is the mixture of different symptoms or other reasons 
[4]. Due to these reasons, it is necessary to improve the knowledge about the patho-
genesis of pain and the modern approaches to the management of pain relief.
2. Pain
According to the last guidelines by the International Association for the Study 
of Pain (IASP), pain is defined as unpleasant sensory and emotional experience 
associated with or resembling that of actual or potential tissue damage [5].
The presence of pain in patients at PC is associated with actual or potential 
tissue damage which has implications on their daily physical activities, produces 
debilitation and mental destabilization and has social consequences. In general, 
pain is a special medical condition which pathophysiology is complex and originates 
from different causes [6].
Many stimulations arising from injuries or destroyed tissues, commonly associ-
ated with prime pathological event in the body, produce noxious stimuli. Peripheral 
painful stimuli are detected by nociceptors, which are free nerve endings located in 
tissues and organs. Following complex mechanisms, the noxious stimuli are trans-
formed and recognized by the brain as pain [7].
The released neurotransmitters and neuropeptides enable the pain stimuli to 
ascend to the thalamus and midbrain through two main tracts, the spinothalamic 
tract and the spinoreticular tract (involved in descending inhibition of the pain) and 
through the spinomesencephalic tract. They go from the spinal cord, are synapsing 
in the periaqueductal gray meter in the midbrain and are involved in the modulation 
of the pain [8]. Descending pathways descend in the dorso-lateral fasciculus and syn-
apse in the dorsal horn inhibitory tracts; they are coming mainly from areas (periaq-
ueductal gray matter, the raphe nuclei, and the locus ceruleus) in the brainstem tracts.
Modulation of the pain is a process of inhibition or amplification of the pain 
signals [9]. It happens along its ascending pathways on several levels, at segmental 
level (the primary afferent neuron and dorsal horn), supra-segmental level (mid-
brain) and cortical, or through the descending pathways. In this process the follow-
ing excitatory substances are included: excitatory amino acids (EAA), acetylcholine 
(Ach), glycine, substance P (sP), Oxytocin, central corticotropin releasing hor-
mone (CRH), and the inhibitory substances as serotonin, noradrenalin (NE), and 
gamma-amino butyric acid (GABA) including endorphins (eg, enkephalin) [10].
Many drugs are acting as modulators of pain. They are acting at segmental level 
(local anesthetics), supra segmental (opioids, non-opioids, and adjuvants), and 
central or cortical levels (opioids). The endogens opioids endorphins and enkepha-
lins are acting via the descending system and are responsible for the analgesia 
induced by stress.
Modulation and perception are the component of the plasticity of the pain. Pain 
plasticity is a result of the possibility of the nervous system to modify its function 
under different conditions [9]. For the perception of the noxious stimuli and the 
formation of the memory of the pain, the middle and higher levels of the brain are 
responsible. The subconscious pain information’s are ended in sub cortical level at 
hypothalamus, thalamus, amygdale, and hippocampus. They are transferred to the 
cortical centers where they are recognized as pain in somato sensory cortex, insula, 
and anterior cingulate cortex [10].
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In general, pain can be acute (physiological) and chronic (pathological). Some 
authors make a distinction between physiological and pathological pain, classify 
it as Nociceptive (somatic, visceral), and Neurophatic (burning along the nerves, 
dysesthesia, allodynia, Hyperalgesia) [11]. Under certain conditions, acute pain can 
become maladaptive and non-protective and turn to pathological, dysfunctional 
pain - chronic pain.
The evidence concerning pain among patients in PC show that during the care 
phase, pain is present in one moment in approximately 70–90% of the patients [9]. 
Pain is seen in many end stage diseases. The prevalence of pain is most common 
in cancer; 70–90% in latter stages of the illness and 33–70% in patients receiving 
treatment [12]. Comparatively, the prevalence of chronic pain in the general adult 
population ranges from 2% to 40%. It is known that back pain alone affects “up to 
84%” of adults.
Many conditions in palliative settings could provoke the pain. Mainly they are 
caused by the primary diseases, disorders, and conditions. An accidental situation 
such as trauma, blunt trauma, broken bone, burning, electrical injury, eye injury, 
heart attacks or postoperative state (amputation, removal of a part of an organ) 
needs corresponding analgesia. In chronic illnesses from circulatory, infectious, 
or malignant origins, the pain is expressed as neural compression or malignant 
infiltration, bone metastasis, obstructions, and infiltration of the soft tissues. Many 
degenerative processes produce inflammation and are reason for pain.
Resulting from the type of the pain, the feeling pain is different. The pain is 
reported as dull, achy, stabbing, shooting, burning, severe, or pins-and-needles 
sensations.
The patients on PC fear pain because of its physical, emotional, and psycho-
logical components [3]. Unrelieved or undertreated pain with all its effects to the 
body systems, may transit to chronic pain. The pain experience is unique for each 
individual and the way everyone perceives pain, and its severity is different, leading 
to changes in the personality that has social implications. If the pain is with chronic 
persistence, it disturbs the sleep and appetite, lowers the tolerance to stress and is 
often the reason for depression. There are evidences that pain contributes to the 
development of some cognitive dysfunctions. It impairs attention, memory,  
concentration, and content of thought [13].
The reaction to pain and thresholds to pain are complex and individual and 
depend to the individual experiences to pain. The intensity of the pain is in the 
proportion of the extent of the tissue damage, the severity of the illness and the 
degree of the patients’ discomfort [14]. The after-effects of persistent pain are 
multiple due to stress-reaction with the involvement of the adreno-cortical axis and 
hyperactivity in many organs and systems. Increased heart rate with low cardiac 
output, presence of fear, increase respiration rate, cold vasoconstricted skin, 
neurological dysfunctions and other impairments in homeostasis are often seen 
as associated symptoms to the pain [15]. Patients with chronic pain may have low 
levels of endorphins in their spinal fluid [16].
Modifications of the quality of the pain are product of different physiological 
and psychological phenomena. The protective function of the pain has function to 
restore the homeostasis at both levels (autonomic and psychological). The intensity 
of pain can be modulated by psychological factors where emotions have an impor-
tant role in the perception of pain. The memory of pain episodes, the patients’ 
reactivity to pain, families and friends supports, religion, personal defense skills, 
and therapeutic strategies are the most frequent reasons for these modifications [8]. 
The levels of education, culture and tradition have an important part in the forma-
tion of the pain experience. Severe pain produces mental and physical torture of 
the body [17]. The person is exhausted, fatigued and without energy. Fatigue is one 
Palliative Care
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of the leading symptoms of terminal states and often concomitant symptom of the 
malignancy, producing a poor quality of life.
3. New approaches of pain treatment
Pain is a common symptom in many advanced illnesses [18]. Nowadays, the 
treatment of pain is approached from neurobiological, clinical, and behavioral 
perspective.
The main goals of the pain management are early recognition, early proper pain 
relief, monitoring and documentation. New approaches to the management of pain 
in palliative care integrate the standard pain relief methods with complementary 
health techniques [19]. The expectations of the patients at a Hospice are to have 
an active, pain-free life. The potential to reach these expectations is though the 
patients tailored analgesia and the integrations of alternatives with medical treat-
ment in multimodal analgesic approach. A multimodal flexible approach to pain 
relief therapy for palliative care provides the best results. It consists of the use of 
more therapeutic abilities at the same time frame, at different time intervals. The 
main characteristic of this therapy is a continuum of analgesic management [20]. 
The last advancement in pain management treatment is multimodal analgesia with 
individual tailoring of the therapy to the real needs [21].
3.1 The multimodal approach to pain management
The multimodal approach to pain management which was introduced in 1993 
by Kehlet and Dahl as an analgesic model for postoperative pain is already well 
established [22]. The fact that nearly 10–30% of patients with cancer pain were 
not satisfied with the standard pain relief treatment (use of systemic analgesics 
alone) [23] commanded research for new analgesic approaches for more severe 
pain. The complex mechanism of pain in which physical and psychological 
disorders are involved need corresponding therapeutic approaches; complex and 
focused on pain relief, improvement of mental status, psychological treatment, 
education, and socialization. It seems that multimodal approach in pain manage-
ment can reach all those necessities providing less use of opioids for 10–20% 
sparing effect [24].
The multimodal analgesia (MMA) and its opioids sparing effect, provides a 
significant efficacy in pain treatment and takes an important place for curing acute 
or chronic pain in palliative medicine. It involves multiple combinations of drugs 
(opioids, non-opioids, and sedatives), non-pharmacological therapies and some 
specialized techniques to provide better analgesia.A variety of fixed combina-
tions of analgesic drugs are available on the market. In those combinations, the 
paracetamol, and non-steroidal anti-inflammatory drugs (NSAIDS) play important 
part of the multimodal approach to analgesia. Used in palliative setting the multi-
modal approach may meet the individual patient needs of altered nociception and 
the variety of experiencing pain [25, 26].
The main goal of this therapeutic approach is the treatment of pain by targeting 
different physiological causes of the pain.
Data about genetic polymorphism speaks about the necessity to tailor the pain 
management according to the real patients’ need [27]. According to the ladder 
algorithm, selection of non-opioid, opioid, and adjuvant analgesic therapy should 
be adapted to the intensity of the pain [28]. Identification of opioid receptor 
gene regulation, its transcription factors and post-transcriptional events are 
considered as alternative variations in mRNA stability and translation efficiency. 
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Additionally, the development of genes that increase or decrease pain opens a 
new dimension in the treatment of pain [29]. Perhaps the genomic profile of 
every person will be key to more efficient pain control. The choice of certain 
pain strategy and adequate medications are key principles for effective pain 
management.
3.2 Assessment of the pain
The assessment of the pain is the most important part of pain treatment. It is an 
initial step in the evaluation of the level of pain and continues during all pain relief 
episodes, as constant reevaluation of the effects of pain management. An effec-
tive relief of pain depends mainly on a comprehensive assessment to identify the 
different physical, psychological, social, and spiritual aspects. The oral descrip-
tion of the presence of pain is insufficient to express the real patients’ suffering. 
It is more visible by other objective, autonomic and behavioral sights that are 
expressed through mimics, sweating, tears, or with changes in vital parameters in 
the person [4].
The subjective feeling of pain is difficult to be measured, but its effects on vital 
parameters may be measured. Based on this, the evaluation of the pain is being 
based. Generally, there are two main principles: objective (Type I) and subjective 
(Type II) method for pain evaluation. The difference between those two meth-
ods is the opportunity to present the individual feelings of pain in measurable 
values. The objective evaluation is measurable by the detection of the changes in 
physiological, neuropharmacological, and neurological parameters. In the Type 
II evaluation approach, the subjective patients’ feelings of pain, measured by 
self-evaluation, are presented in measurable values- scores. In practice, for PC 
use, more applicable are the less invasive methods, which are present in Type II 
evaluation [30].
Taking anamnesis is the first step which helps enormously, where the patient 
must describe the pain in detail. It is necessary to provide information about the 
severity of the pain, the history – when, where, how the pain appeared, examine 
the location of pain, and to investigate the state of the other systems (imag-
ing, organ function). To assign the appropriate management, it is important to 
discover: the origin of the pain, the states in which the pain is more intensive, the 
quality of the pain, the route of propagation of the pain, and the degree and the 
intensity of the pain. In assessing the symptoms, one can use the OPQRSTUV 
mnemonic (O- Onset, P- Position, Q- Quality, R- Radiation, S- Severity, 
T- Timing, A- Associated features, A- Aggravating Factors, A- Alleviating 
Factors) [19].
The received information helps in understanding the pathophysiology and in 
classification of the pain as nociceptive or neuropathic. An objective evaluation 
of the pain during palliative care is difficult; it is caused by the lack of commu-
nication with the patients so the use of conventional scales for measurement of 
pain is almost impossible [31]. For this reason, for patients in palliative care and 
in children, a multidimensional approach is accepted worldwide [4]. It works by 
using subjective explanations or common methods for self-evaluation of the level 
of pain, and objective signs from behavior and other vital parameters. Subjective 
feelings of the pain are measured with self-evaluation using several scales that 
help in the evaluation of the severity of the pain or pain questionnaires useful for 
children and older people (Table 1). In multidimensional approach the subjective 
methods in Type II evaluation are supplemented with the objective reports of the 




A simple observation can discover any kind of discomfort, lack of interest, anxi-
ety, crying, tears, abnormal position or movement, or changes in vital parameters as 
high blood pressure, tachycardia, sweating, impairment in dieresis and other [30].
3.3 Treatment plan
In the preparation of the treatment plan, it must be considered that pain is a syn-
drome with neuropathic, nociceptive, emotional, and psycho-social overlays and it 
can be used to guide an individually tailored treatment plan because of its subjective 
nature. To improve outcomes, it is necessary to integrate the PC with other settings 
[33]. Patient / family must be involved in the planning of the pain treatment. The 
common problems in planning appear from the conservative believes and myths about 
pain. The existence of the pain is inevitable at the end of the life; the patient/family has 
fears about the use of opioids because of addiction and side effects. For this reason, is 
necessary to discuss the management strategy for pain relief. All parties must be very 
well informed about the multimodal approach and the incorporation of the interdisci-
plinary team in pain management that comprises integration of the use of medicines, 
physical therapy, music, meditation, hypnotherapy, and others alternative methods. 
Additionally, the personal abilities of the patient/family regarding the terminal stage, 
culture, religion, and other socio-economic factor must be taken in consideration.
3.4 Pain services
The pain services as special teams working on pain treatment takes place in or 
out of the Hospices. They could practice pain treatment as “patronage services”, 
Type I – PAIN EVALUATION Type II – PAIN EVALUATION
PHYSIOLOGICAL CHANGES ONE DIMENSIONAL METHODS
Increased Plasma Cortisol Categorical Scale
Increased Plasma Catecholamine’s Numerical Scale
Cardio-Circulatory Changes (Pulse, BP, CVP) Visual Analog Scale
Respiratory Changes (RR, VC, FEV, TV)
Tears, Facial grimacing
NEUROPHARMACOLOGICAL MULTI DIMENSIONAL METHODS
Inverse Correlation with Plasma Beta Endorphins
Changes in Dermal Temperature
Mc GILL Questionnaire
NEUROLOGICAL Dartmaut’ Questionnaire
Changes in Nervous Conductance Velocity List of West Haven-Yale
Evoked potential (neurologic dysfunctions) Pain perception profile





Legend: BP-blood pressure; CVP-central venous pressure; RR-respiratory rate; VC-vital capacity. FEV-forcefully 
expired volume; TV-tidal volume.
Table 1. 
The evaluation of pain [4].
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visiting the homes of persons at the end of their life or patients with cancer pain. 
The goal of such services is to achieve the best care and to improve the life for 
patients and their families.
4. Pharmacotherapy in pain management in palliative setting
In normal conditions, the primary analgesic management in palliative care starts 
with oral administration of the medicines. The WHO in 1986, for nociception pain, 
proposed a “step by step” approach which understands escalation of the drugs from 
non-opioid to opioid analgesics [34].
Primarily the ladder approach was used for cancer pain, but today it is widely 
used for any kind of pain. In 2010, Vargas-Schaffer G. suggested a re-adapted four 
steps ladder [35] (Figure 1), which in 2012 was revised by Leung, who advised pain 
treatment in a tridimensional multimodal platform [36], and at list, in 2019 Cuomo 
introduced the trolley model for multimodal tailored therapy [37].
The administration of drugs in palliative care is recommended to be less invasive. 
When possible, the most appropriate method is oral administration. Also, among less 
invasive methods well accepted by the patients are rectal or transdermal (patches) 
application. When it is necessary to apply the invasive parenteral routes, intra venous 
(IV), intramuscular (IM), subcutaneous (SC), can be considered. Dosing is different 
and varies depending on the type of the pain from around-the-clock dosing, “as-
needed dosing” to “patient-controlled analgesia (PCA)”.
4.1 Non-opioids
Non –opioids are a group of medications consisting of anti-inflammatory and 
non-steroidal anti-inflammatory drugs. They have antipyretic, anti-inflammatory, 
and anti-platelet effects. Their use in palliative care takes an eminent place because 
most of the etiological factors of the pain are related to inflammation. Traditionally 
they include anti-inflammatory drugs such as salicylic acid, paracetamol, and non-
steroidal anti-inflammatory drugs (NSAIDs), which remain the major players for 
the treatment of pain in PC [38]. They have an opioid sparing effect when used in 
multimodal therapeutic approach (see below).
Figure 1. 
Readapted WHO ladder for analgesic management [22]. (legend: NSAIDs- non-steroidal anti-inflammatory 




Acetaminophen (paracetamol) chemically belongs to para-aminophenol 
derivatives; it is an active metabolite of phenacetin with an analgesic-antipyretic 
property and weak anti-inflammatory activity. It is recommended as a first step 
analgesic for mild to moderate pain [39]. Its mechanism of action is based to inhibi-
tion of central prostaglandin synthesis in the central nervous system and possible 
increases of noradrenaline in CNS and peripheral beta-endorphins [40]. It describes 
its analgesic and antipyretic activity without any effects on inflammation. Its use 
in PC is crucial on its formulations in form of tablets, coated tablets, or ampoules; 
therefore, it can be administered orally or IV. The onset of action for oral form is 
slow (15 min), so the use of intravenous application is the more appropriate. The 
maximum recommended therapeutic dose is 4000 mg/24 h, or 80/kg BW/24 h. 
According to a Meta analyses made from Schüchen RH et al. (2018), it was shown 
that there was no conclusive evidence that Acetaminophen in treatment of cancer 
pain produces satisfactory pain relief [41], but often it is used in combinations with 
opioids and it shows a decrease of the need for opioids (spearing effect). Its metab-
olites contribute to the toxic effects, so doses over its maximum dosage provoke liver 
damage. Therefore, it must be used with precaution in patients with liver diseases.
Aspirin (acetylsalicylic acid) chemically belongs to the group of salicylates [42]. 
It is the most widely used drug for the treatment of mild to moderate pain. Aspirin 
has an analgesic-antipyretic, anti-inflammatory effect and prevents clotting. It is 
usually used for pain relief with low intensity. Its mode of action is through the 
decreased production of prostaglandins and thromboxane A2 by an irreversible 
inactivation of the ciclooxygenase enzymes (COX). It is an important additional 
medicine for patients with severe inflammatory pain (rheumatoid arthritis and 
similar). It is suitable for long-term use, because it is safe, with lower toxicity than 
paracetamol or opioids. In PC it can be safety used for pain control of acute pain, 
such as headache, toothache, minor back pain, for prophylaxis of myocardial 
infarction due to its well-established anti-platelet action. Its formulation is prepared 
in tablets and suppositories (100 mg, 300 mg, and 500 mg). Its use is 4–6 times per 
day, with maximum dose of 3000 mg/24 h. Among its side effects, the most impor-
tant are appearance of peptic ulcer, allergy to salicylates and development of Reye’s 
syndrome, if it is used in children younger than 16 years old. Overdosed, aspirin 
can cause cardiovascular instability, exacerbate underlying renal insufficiency, and 
even lead to coma with renal failure, metabolic acidosis, and respiratory arrest [42].
4.1.2 Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of potent 
analgesics, antipyretics, and anti-inflammatory agents which are efficient in 
reliving of moderate to severe pain from musculoskeletal origin. They are widely 
in use at the institutions of palliative care as mono or combined therapy. The 
list of NSAID medicines is long and, in this document, only the most often used 
drugs will be mentioned. The NSAIDs mode of action is through peripheral and 
central inhibition of prostaglandin production from arachidonic acid through 
acetylating of two cyklooxygenase isoenzymes (COX-1 and/or COX-2). The non-
selective NSAIDs inhibit the activity of both cyklooxygenase - COX-1 and COX-2. 
The most often used non-selective NSAIDs are ibuprofen, ketonal, diclophenac, 
naproxen, etc. [43].
On the other side, the selective inhibitors to isoenzyme COX-2 (celecoxib, valde-
coxib and rofecoxib) have the same analgesic effects as the non-selective NSAIDs, 
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but with a reduced risk for gastrointestinal tract (GIT) and platelets that makes 
those acceptable for pain management [44]. Unfortunately, the COX-2 inhibitors 
in 2001–2010 failed to be adopted because of cardiovascular side effects [45]. Some 
authors described the development of acute myocardial infarction and sudden car-
diac death, and in 2004 rofecoxib was withdrawn from the market. However, some 
additional studies show that inhibitors to isoenzyme COX-2 are powerful agents 
for control of intractable pain. They also have antitumor effects and are suitable for 
treatment of patients with bone metastasis what is due to inhibition of the produc-
tion of cytokine and prostaglandin responsible for solid tumors and bone pain [46].
4.1.3 Recommended non-conventional non-steroidal anti-inflammatory drugs
They are used in palliative medicine for the treatment of moderate and severe 
chronic pain, alone or in combination, including cancer pain:
Metamizole or dipyrone is an old non-opioid drug patented in 1922 in Germany. 
It has analgesic, antipyretic, spasmolytic, and fewer anti-inflammatory effects. 
The possibility to provoke a life-threatening agranulocytosis after long use made 
metamizole for a long time to be under scrutiny. It was restricted in many countries 
in the world, but today after relevant clinical studies, the evidence has changed. 
Now, metamizole is recommended as an effective pain reliever in treatment of acute 
pain, particularly for renal colic and acute pancreatitis. It is found in form of tablets, 
suppositories, and injections for IM use [47].
Ketorolac is the most widely used non-steroidal, anti-inflammatory drug for 
treatment of moderate to severe pain in adults. Its mode of action is by blocking 
both cyklooxygenase (COX1 and COX2) and decreasing the prostaglandin produc-
tion. Its’ medical use dates to 1989, predominantly for postoperative pain relief. It 
is found in form of tablets, nose spray, injection for IM and IV use, as well as eye 
drops. Its use shows many benefits. It is an efficient analgesic, an opioid sparing 
NSAID drug, and improves the bowel motility what makes it suitable for postopera-
tive analgesia in abdominal and obstetric surgery. Its adverse effects limit its use up 
to 6 days [48].
4.1.4 Toxicity of NSAIDs
In general, the use of non-steroidal and NSDAIDs in recommended therapeutic 
doses is well tolerated, but they contribute in various degrees to gastrointestinal 
(GI), renal and cardiovascular (CV) toxicity. In 2003 Schung SA and all [49] studied 
the efficacy and potential toxicity of opioids and non-opioids. They concluded that 
paracetamol used in therapeutic doses is safe, but an overdose is fatal, requiring 
specific treatment. The inhibition of the activity of COX-1 provokes impairment of 
gastric mucosa, renal parenchyma, and platelet function, manifesting several life-
threatening side effects. The most important are the development of gastrointestinal 
bleeding, asthma, renal dysfunction, hepatotoxicity, cardiotoxicity, and others.
There are general recommendations for the choice of NSAIDs in palliative medi-
cine based on individual risk of GI or CV toxicity [50]. With the aim to avoid any 
GI risks, all patients on regular NSAIDs/COX-2 inhibitors -therapy, must receive 
proton pump inhibitors (Table 2).
NSAIDs used alone may not achieve its satisfactory effects; the combination of 
NSAIDs and step III opioids showed beneficial effect [38]. The essential drugs for 
palliative care are drugs that are effective for the treatment of common symptoms 
in palliative medicine, easily available, and are affordable, and are ones that cor-




They are particularly important medicines in PC for treatment and control of 
moderate to severe, acute, or chronic pain. Opioids are a group of medical agents 
that have opium or morphine –like properties with analgesic and many other 
pharmacological effects. In the past, their use was limited by the clinicians as 
undesirable drugs, especially in high doses, because of its possibility for addiction 
and appearance of several side effects, including respiratory depression.
Nowadays, as the population ages, with an increased prevalence of chronic pain, 
it has been agreed that this concern was unfounded. The new multimodal approach 
for pain control, the development of safer opioids analgesics and the use of opioids 
sparing agents, promise more regular prescription [42]. Cancer’s intractable pain 
remains the most horrific condition where opioids take an eminent place in the 
treatment [43]. Concerning the ladder algorithm for severe pain, patients tailored 
therapy to its need, provides the right choice of opioids, non-opioids and adjuvant 
leading to more satisfactory pain relief [52].
Today it is accepted that opioids act on an endogenous opioidergic system 
which controls the nociception, and participates in modulation of other functions 
as autonomic, GI, endocrine or cognition. Exogenous opioids administered in the 
body have the affinity to bind with several distinct types of receptors for opioids. 
These receptors are the previously known G-protein-coupled receptors: “delta”, 
“kappa” and “mu”, which were named according to the exogenous ligand or tissue 
where they were isolated. By a recommendation from the International Union of 
Pharmacology (IUPHAR), in 2000 the opioid receptors were renamed to DOP, KOP 
and MOP [53].
The identification of the MOP receptors and the isolation of its protein helped in 
more profound study of the structure and pharmacological properties of morphine. 
The opioid receptors are found in peripheral and central nervous system including 
spinal cord (PNS & CNS). They are found also within vas deferens, GIT, heart, 
immune system, and knee joint. The endogenous opioids peptides, active ligands 
to the receptors, were identified in the brain extract, having analgesic properties 
similar as morphine, and known as “endogenous opioids”. Endogenous opioids in 
CNS are derived from their precursors: pro-enkephalin, pro-opiomelanocortin, 
pro-dynorphin, and pre-pro-N/OFQ (pp-noc), and function as neurotransmitters 
important in control of hormone secretion, thermoregulation, and cardiovascular 
system [54]. The opioids’ receptors are presented at Table 3.
The main event is in the CNS where, by the opioids activated MOP receptors, the 
descending inhibitory neurons producing opioids are activated –induced analgesia.
Opioids are divided upon its pharmaco-chemical origin in naturally occur-
ring, semi-synthetic and synthetic compounds. According to their activity at 
opioids receptor, they are divided to agonists, partial agonists, and antagonists. 
Drugs Only GI problems CV problems/±GI CV/GI problems No CV/GI problems
NSAIDs Avoid if possible, if is 
essential:
Celecoxib 200 mg/24 h










Legend: GI-gastrointestinal; CV-cardiovascular; CV/GI – bough (gastrointestinal and cardiovascular).
Table 2. 










































Analgesia, sedation, nausea, vomiting, 









DOP Pro-enkephalin [Met]-enkephalin 
[Leu]-enkephalin







KOP Pro-dynorphin Dynorphin A/B Spinal analgesia, dieresis, dysphoria Low Affinity; Butorphanol Buprenorphine Low 
Affinity;
NOP Pre-pronociceptin N/OFQ Spinally–analgesia, hyperalgesia&allodynia; 
Intracerabrovasular antianalgesic effect
X No Affinity; X No Affinity X No Affinity
Table 3. 
Opioid receptors, endogenous ligands, and clinical drugs.
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Agonists are all opioid drugs which by binding to the receptors produce complete 
response morphine-like. Antagonists binding to the receptor have functional 
response and prevent binding of an agonist (naloxone). Partial agonists provide 
only partial functional response which is not corresponding to the amount of the 
drug [55].
According to the ladder algorithm, which is in use in palliative care centers, the 
opioids are divided upon their power in weak and strong opioids. In the following 
text, this classification will be taken in consideration.
4.2.1 Weak opioids
4.2.1.1 Tramadol
It is centrally acting non-opiate analgesic with low affinity for MOP receptors 
and is effective in the treatment of moderate to severe pain. It has modest affinity 
to MOR and has weak interaction with DOR and KOR receptors. Because of its 
non-opioid properties, it is included in bouts group as weak non opioid agent with 
centrally acting analgesic effect and is favorable for PC use. As it possesses MOR 
agonist properties, it also, through the activation of monoaminergic spinal inhibi-
tion of pain, acts in inhibition of the reuptake of serotonin and norepinephrine, 
which synergistically enhances its weak opioid mechanism of action [56].
Chemically tramadol is present in two isomers which separately (one or other) 
inhibit the reuptake of noradrenalin or serotonin. The activity of tramadol depends 
on its metabolic activation which differs among the patients. Its’ use is convenient 
for treatment of acute and chronic pain, moderate and severe, from cancer and 
non–cancer origin, as diabetic neuropathy, and fibromyalgia as well.
Tramadol is found as tramadol hydrochloride in form of tablets or capsules 
(50 mg, and 100 mg) for oral use 4–6 times per day, and in injections of 2 ml (50 or 
100 mg/ml) for IV, SC, IM and via spinal routes. The maximal daily dose is 400 mg 
which could be exceeded only in special clinical circumstances. Clinically used for 
moderate pain, can provoke some adverse reactions as, dizziness, nausea, sedation, 
dry mouth, sweating and gastrointestinal dysfunctions. It is an extremely popular 
drug used for pain relief in PC in musculoskeletal injuries and as postoperative 
analgesic drug.
4.2.1.2 Codeine
It is used as a weak opioid. It is a naturally occurring substance derived from 
opium (opiate) and is a pro-drug of morphine. Codeine is metabolized in the 
liver and is excreted through the urine. About 10% of codeine by demethylation is 
converted to morphine [57]. Codeine has incredibly low affinity to opioid receptors - 
200 times lower than morphine; its analgesic property is due to converted morphine. 
Its dominant use is orally, in the form of tablets or suspensions, for control of mild to 
moderate pain, coughing and diarrhea. It is a drug with reliable effects, and particu-
larly useful in PC for pain relief. It can be used alone or as a combination with some 
non-opioid drugs, which increases its analgesic profile. The onset of its effect is after 
30 minutes, with maximum effect at two hours and its offset about four to six hours. 
It comes in form of tablets (15 mg, 30 mg and 60 mg), a liquid (25 mg/5 ml spoon) 
to swallow, and syrup (15 mg/5 ml) or as an injection-codeine phosphate - of 2 ml 
(60 mg/ml). The dose is repeated every 4 hours and should not exceed more than 
4 times per day. The adverse effects of codeine are like all opioids: constipation, 
nausea, vomiting, drowsiness, lightheadedness, confusion, euphoria, vertigo, dry 
mouth, headaches, pruritus.
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The safe treatment of codeine understands titration of the doses of codeine 
(starts with a small dose of the drug and gradually increases it, until a satisfied 
result of complete analgesia is obtained). Symptoms of overdoses of codeine are also 
like those of morphine and other opiate analgesics. They are miosis, sweating, cold 
skin, respiratory depression, bradycardia, hypotension, skeletal muscles flaccidity 
and other which need an emergent resuscitation.
Hydrocodone is a more potent synthetic opioid, hydrogenated ketone deriva-
tive of codeine. It is selective full agonists to MOP receptors. It is used for control of 
moderate to severe pain. It comes in form of tablets (5 mg and 10 mg) for oral use. 
Its duration of action is 4–5 h, and plasma half-life of 4 h. It is typically available in 
combination with acetaminophen or ibuprofen, which is very well suited for the 
treatment of mild to moderate pain syndromes in multimodal analgesia. In the past, 
hydrocodone has been used as a cough suppressant. For the treatment of severe 
chronic cancer pain, it has found a wide use with prolonged duration and the more 




Morphine is a strong naturally occurring opiate, isolated in 1805 from the poppy 
straw. Morphine is a “gold standard” among the opioids, against which the other 
drugs are measured in equal-analgesic doses. Morphine is a full MOP agonist with 
appreciable affinity to DOP and KOP. Its major effects are apperceived on parts of 
the CNS (posterior amygdala, hypothalamus, thalamus, nuscleus caudatus, puta-
men, and some cortical areas), producing drowsiness, analgesia, changes in the 
mood. MOP agonists further inhibit gastrointestinal tract (GIT) secretions and 
peristalsis; often causing constipation, also present is decreased bowel motility, 
vomit, nausea, and other sensations. MOP opioids also have effects on the cardio-
vascular system, thermoregulation, hormone secretion and immune function [59].
Morphine in PC is primarily used to treat acute and chronic severe pain and is a 
drug of first choice in PC for treatment of moderate to severe cancer pain. The oral 
formulation is easy for administration and especially useful for long treatment. It 
comes in form of tablets (30 mg, 60 mg, 100 mg), sub-lingual pastilles (60 mg), or 
as solution/suspensions (10 mg/5 ml). It is also valuable as injections (for IV, IM, 
SC, or PCA), rectal and spinal applications. In some countries extended-release 
capsules are present and extended-release tablets which are prescribed 1–2 times 
in 24 h. They are suitable for patients who are long time on morphine treatment. 
The onset of analgesic activity appears in 30 minutes, reaching the peak effect at 
60–90 minutes. The average plasma half-life is 3 hours with offset of 6 h. The rest of 
morphine in plasma is present up to 15 hours [49]. The best way of the application 
of morphine is titrating of the doses. As it has no roof of its effect, the cure starts 
with small dose which may be increased by 30–50% every 12–24 hours until the 
optimal control of the pain. The titration continues to maximum tolerability, before 
moving on to another opiate [60].
Proper dosing of morphine is especially important for elderly patients in PC 
institutions. They may be overly sensitive to the effects of morphine and a continu-
ous monitoring of the respiration, blood pressure (BP) and the level of conscious-
ness is necessary to be performed.
The clinical use must be corresponding to the current recommendations at 
national or institutional levels. In most of the recommendations it has been shown 
that starting with a low-dose oral morphine (eg ≤30 mg/day) gives better pain 
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relief than using weak opioids. National Institute for Heath and Care Excellence, 
UK, (NICE) [61] in its Guidelines recommends that morphine should be used as 
first-line oral opioid for relief of cancer pain. It is also recommended for children 
with cancer pain; in the guidelines of the Royal Children’s Hospital Melbourne, it 
is advised the use of oral morphine for children over six months with start dose of 
0.2–0.5 mg/kg/dose, every 4-6 h orally [32].
The adverse effects of morphine include sedation, cognitive impairment, 
nausea and vomiting which are frequently seen. Also seen are respiratory 
depression, etching, circulatory disturbances, hormonal imbalance with hypo-
gonadism, immunodeficiency, changes in the mood with hallucinations and 
depression. Constipation is seen with chronic therapy; patients do not develop 
tolerance to it and typically require preemptive treatment with laxatives. 
Also seen are tolerance or intolerance to morphine and addiction. The genetic 
approach confirms that those effects of morphine are result of the action at the 
MOP receptor and N/OFQ–NOP system [62, 53].
Many opioids are made by the modification of the morphine molecule, as 
Apomorphine, Oxycodone, Hydromorphone. They have similar properties as 
morphine and only the specificity of their use in PC will be mentioned.
Oxycodone–is a synthetic opioid, with high selective affinity to MOP and low 
affinity to DOP and KOP receptors, working as typical agonist. It is used for treat-
ment of moderate to severe pain, is metabolized hepatically to the active oxymor-
phone [63]. It comes in form of tablets with immediate and controlled release of 
action or in injection. The onset of the analgesic effect starts within 15 minutes and 
it is used widely as analgesics especially for postoperative pain. One study com-
pared the controlled-release oxycodone and morphine tablets in 45 cancer patients 
and was found that both were transformed in liver to the active oxymorphone. 
Oxycodone was the most often used drug in USA in the last two decades and was 
responsible for the “opioid crisis” due to – “too much free use” of this drug [64]. It is 
a particularly good pain killer and because of its oral application it is recommended 
for patients at PC. It develops the same side effects as other morphine like drugs.
Hydromorphone- is a water-soluble opioid that is several times more potent 
than morphine allowing for smaller dosage. It is found in parenteral, rectal, 
subcutaneous, and oral formulations. It is also used for epidural and intrathecal 
administration for postoperative pain relief or when other ways are not appropriate 
[65]. It was shown more effective pain relief properties for continuous dull pain and 
provides superior analgesia when is mixed with epinephrine.
Meperidine- is a synthetic analgesic drug indicated for the treatment of 
moderate to severe pain. It is delivered as hydrochloride salt found in form of 
tablets (50 and 100 mg), emulsion, or injections. It is predominantly a MOP 
agonist with main action on CNS and the bowel. Its analgesic effects exceed after 
15 minutes and the peak effect after 45 minutes. The effectiveness of parenteral 
application is the same as that of morphine. The adverse reactions are like those 
of other agonists [63].
Methadone- is synthetic opioid, MOP agonist, which is used for pain relief 
in PC. Its pharmacological profile is like that of morphine, but it has a very long 
half-life with considerably longer duration of action. It is also an antagonist of the 
N-methyl-D-aspartic acid (NMDA) receptor [64]. Methadone is without any active 
metabolites but is found as racemic mixture of 2 enantiomers; the R- methadone 
is responsible for analgesic effects, while S-methadone is a NMDA antagonist. It 
has little tendency to induce tolerance in patients, which makes it suitable drug 
for treatment of opioid dependence. It has unique properties that make it useful 
in treating pain which is poorly controlled by other opioids. Its dosing is flexible, 
although it can be used in neuropathic and somatic pain relief. It is safe for patients 
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with renal impairment and is only long-acting liquid opioid. As a result of the lack 
of knowledge of its metabolic changes, it has possible interactions with other drugs, 
and its’ long half-life made, methadone is seen to be an incriminated drug [59].
Fentanyl-is a synthetic powerful opioid, related to phenyl piperidine family that 
includes sufentanil, alfentanyl and remifentanil, with similar properties to the other 
opioids, selective MOP agonists. It is a powerful analgesic, lipophylic opioid, quick 
acting drug which is 70 to 100 times more potent than IV morphine.
Fentanyl is used for treatment of severe acute and chronic pain, as a medicine for 
anesthesia, for postoperative pain relief and in the treatment of intractable cancer 
pain in PC. It is available in parenteral, transmucosal, and transdermal formula-
tions. Intravenous fentanyl has very rapid onset of action 5 minutes to peak analge-
sia, with offset of two hours. Fentanyl and its forms administered in intrathecal and 
epidural space provide prolonged postoperative analgesia up to 8 hours [50].
Because of the variety of forms, fentanyl has become the most widely used drug 
in palliative medicine. It is found in form of fentanyl buccal soluble film (FBSF), 
fentanyl buccal tablets (FBT), fentanyl pectin nasal spray (FPNS), oral transmuco-
sal fentanyl citrate (OTFC), intranasal fentanyl spray (INFS), sublingual fentanyl 
and transdermal patches (FTP) [66]. Most of those forms are extremely valuable 
for analgesia of patients whose oral access is compromised, or with existence of pro-
fuse nausea and vomiting, limiting the swallowing of the required dose of opioid. 
The lowest transdermal dose of patch currently available is 2.5 mg which delivers 
25 mcg/h of transdermal fentanyl. Due to its quick effect, Fentanyl is the drug of 
choice in control of breakthrough cancer pain (BTcP) [67].
Buprenorphine - is a semi-synthetic highly lipophilic opioid. It has partial MOP 
agonist properties and has been in clinical use for over 25 years for treatment of 
acute and chronic pain [63]. Recent studies have confirmed that buprenorphine 
binds with high affinity to MOP and KOP opioid receptors, and with relatively 
lower affinity to DOP receptors. It is found in several formulations for parenteral, 
sublingual, and transdermal use. It is also used as supplement to anesthesia and 
for psychiatric disorders (treatment of opioid addiction). Now Buprenorphine is 
widely used for cancer pain management. There is still debate about the potential 
damage of the transdermal patch and most of the authors think that because of this 
reason it is not suitable for PC [68]. As an opioid, a respiratory depression could 
occur, but it does not response to naloxone. The lowest patch strength of buprenor-
phine (5 mcg/h) is suitable for opioid naive patients.
Tapentadol is a new, centrally acting analgesic agent approved in Europe in 
2010, used for treatment of acute and chronic, moderate to severe pain. Its molecu-
lar structure is chemically like tramadol. It has a dual mode of action, as a MOP 
agonist and a norepinephrine reuptake inhibitor. This metabolic change makes it a 
more potent opioid.
Its potency is somewhere between tramadol and morphine, like hydrocodone, 
oxycodone, and meperidine with more tolerable side effects profile [58–60]. Its 
formulation is in a form of tablets and solutions; tablets for immediate release (IR) 
of 50 mg, 75 mg, and 100 mg, are indicated for treatment of acute to moderate 
pain, with maximum toxic dose of 700 mg/day. For treatment of chronic pain, it is 
advised to use tablets with extended release (50 mg, 100 mg, 150 mg, 200 mg, and 
250 mg). This formulation for long-release, with once-daily dosing of Tapentadol 
is especially acceptable for treatment in PC of chronic severe pain because of 
its simple use and more powerful effect [69]. The daily dose must not exceed 
500 mg/24 h.
Clinical studies show that tapentadol is efficient pain reliever in various pain 
settings including PC setting. In a Clinical trial (NCT01500317) where the adverse 
effects of tapentadol with the equivalent doses of oxycodon were compared, 
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tapentadol reported significantly lower incidence of GI side effects [70]. Its charac-
teristics offer an improvement in pain therapy, and easier coping with severe pain 
for PC patients.
The described side effects are like those of other opioids- such as development 
of allergy, nausea, vomiting, and loss of appetite; dizziness, worsening tiredness 
or weakness may be seen in some consumers. Overdose, addicting, and abstention 
syndrome are also present with an inappropriate use of the drug.
“Breakthrough cancer pain” (BTcP) - is a state of chronic pain with adequate 
analgesia where a temporal intensive peak pain occurs, interrupting the state of 
controlled pain. Traditionally the patients with cancer pain were treated with oral 
opioids, but for the treatment of BTcP it is recommended the fast-realizing forms 
of fentanyl (FPNS or INFS). Some authors reported good response to short-acting 
immediate-release (IR) oral opioid in advanced cancer, supporting the use of these 
opioids in clinical practice [67]. In this context, the National Institute for Health 
and Care Excellence guidelines do not recommend transdermal opioids as a first-
line treatment, when oral opioids are appropriate, specifically fentanyl formula-
tions, are now the gold standard for BTcP due to rapid action and high efficacy.
4.2.2.2 Side effects of the use of morphine and morphine like opioids
The development of constipation, nausea and vomiting; delirium, hallucina-
tions, sedation, myoclonus, hyperalgesia, seizures, headaches, euphoria, or 
dysphoria are often seen as adverse reaction to morphine like opioids. Respiratory 
depression or non-cardiogenic pulmonary edema can appear. Pruritus, urinary 
retention and altered renal function may be seen also, and signs from CV system as 
bradycardia and hypotension as well, hypogonadism, sexual dysfunction, osteopo-
rosis and impairment in the immune system, physical dependence, and the toler-
ance to the drugs [71].
In most of the Guidelines for PC is emphasized that during the pain management 
at the end of life, addiction should not be an issue [61, 72, 73]. It is also reported 
that development of life-threatening overdoses of morphine and morphine like 
opioids in palliative setting is exceedingly rare. In 2005, the American Assembly of 
Nurses referred that overdoses may be avoided with rational prescribing of opioids, 
proper conversion to other drugs, titration and use of adjuvant analgesics [74, 75]. 
The proper titration of opioids and multimodal approach with the use of other 
techniques such as radiotherapy, bisphosphonates, and other medicines in [76] Ca 
pain management, or increased dose of current analgesics, and adding adjuvants 
analgesic for neuropathic pain, may help patients in PC to easier cope with severe 
pain without a danger for overdoses.
At the commencement of therapy with opioids, sedation and drowsiness 
appeared, which are common side effects of opioids. The use of light stimulants 
such as caffeine, or methylphemidate [32] may be helpful. Other mental dysfunc-
tions such as euphoria, dysphoria or nightmares need some additional treatment.
The main sign of overdose with morphine and morphine like opioids, besides 
drowsiness, is the appearance of respiratory depression (respiratory rate - RR < 8/
min, SpO2 < 90% and cyanosis). Because of the progression of the main disease, 
the respiration at the end of the life could be slow, shallow, and noisy, what may be 
misunderstood as a respiratory depression. The recommendations proposed by the 
North East London Cancer Network (NHS)-2018, did not advise immediate use of 
antagonist naloxone for treatment of respiratory depression. The reason for that is 
the ability of naloxone to break the optimal analgesia and produce a “pain crisis” 
which is distressing for the patient and the family [77].
It is advised to use a conservative protocol for such events, which is as follows:
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If the patient with slow RR (8/min) is not dying, has no cyanosis and is rousable, 
the measure “wait and observe” must be performed. If the RR decreases (<8/min), 
the patient is unconscious, cyanotic with SpO2 < 90% and tachycardia, opioids 
should be stopped and an oxygenation via mask should be administered. The treat-
ment compromises of emergent resuscitation and application of MOP antagonist, 
naloxone. Naloxone (0.4 mg/ml) is given as a diluted solution of 0.04 mg/ml. The 
start of the application is with 0.5 ml of diluted solution (0.02 mg), and this dose is 
repeated until higher responsiveness is obtained [65]. If the patient is not treated, 
the respiratory depression can cross to respiratory arrest, with hypoxia, cyanosis, 
hemodynamic instability, hypotension until shock and death [63].
4.3 Adjuvant analgesics
They are drugs with indications different than analgesia. Today is known that 
adjuvants in combination with some analgesic drugs produce efficient analgesia. In 
use are several groups of medicines: antidepressants, antiepileptic drugs, cortico-
steroids, NMDA receptor antagonists and others [78].
The tricyclic antidepressants (TCA) adjuvant agents are very well accepted by 
patients with cancer pain due to their positive effects on the mood and sleep. 
Amitriptyline 1–2 mg/kg oral is a useful agent for treatment of children with 
nocturnal pain, neuropathic pain or sleeping difficulties. Amitriptyline, imipra-
mine, doxepin, and clomipramine are also useful and attractive drugs for MMA of 
the patients in PC and for treatment of neuropathic pain. Because of common side 
effects of TCA, is advised the use of Nontricyclic compounds as safer [79]. Some 
authors suggest that the use of secondary amines desipramine and nortriptyline, are 
less anticholinergic and could be better tolerated than tertiary amines [80]. It has 
been also shown that trazadone, a nontricyclic antidepressant, has the same effec-
tiveness as amitriptyline [81].
Antiepileptic drugs (AED) can offer a remarkably effective treatment strategy 
in combination with opioids and non-opioids in MMA. It has been proposed that 
pregabalin and gabapentin, which are effective in neuropathic pain, target acces-
sory α2δ subunits of Ca2+ channels. An alternative mechanism of action has also 
been suggested - that additionally gabapentin blocks spine morphogenesis [82]. 
The initial daily dose of 100–300 mg of gabapentin can be increased every 3 days. 
The usual maximum dose is 3600 mg daily. It was reported that carbamazepine, 
lamotrigine, levetiracetam have been efficacious in alleviating different neuropathic 
pain syndromes and cancer pain. Precautions must be taken at liver function and 
bone marrow: suppression is possible to develop.
Corticosteroids are frequently used in PC as an adjuvant therapy for cancer 
related pain syndromes, which include bone pain, neuropathic pain from infiltra-
tion or metastatic compression of neural structures, headache due to increased 
intracranial pressure, or if the pain is from inflammatory origin (nerve, bone). If 
the pain is aggravated by tension or muscle spasms, the use of muscle relaxants can 
play an important role in relieving the pain [83], sedation and anti-cholinergic are 
present as side effects.
Bisphosphonatesas adjuvant can help control the pain in certain situations such 
as: cancer-related neuropathic pain [84], in prevention of fractures in people whose 
cancer has spread to the bone, in metastatic bone pain, bone pain, breast cancer, 
bone fractures, osteoporosis with past fracture, etc.
NMDA antagonists has been shown that play an important place and are efficient 
modulators of the pain in postoperative allodynia and hyperalgesia. A representa-
tive of this group is Ketamine, a dissociative anesthetic which is used for analgesia as 
well. It produces, sedation, amnesia, and as an adjuvant sufficient analgesia.
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It is used for treatment of severe acute and chronic pain. Its mechanism of action 
is complex but acts mainly as an antagonist of the NMDA receptor.
Ketamine is given through IV, IM, SC, oral, rectal, nasal, transdermal, epidural, 
and intrathecal way. It is a safe drug, without effects on respiration at analgesic 
doses, and less nausea and vomiting compared to opioids [85]. It is used with 
success in treatment of postoperative pain, refractory neuropathic pain syndromes, 
and severe Hyperalgesia as well. Its use in PC is controversial and is based on few 
un-homogeny studies and with a variety of obtained results. Recent study examin-
ing refractory cancer pain showed that ketamine used at moderate doses provides 
efficient analgesia [86].
Canabis still is with limited evidence of its use. The recent controlled trials and 
studies are unable to answer to the questions about its analgesic efficacy [87].
5. Invasive analgesic techniques
When the pain is refractory to pharmacological treatment, it is advised the 
use of invasive analgesic techniques. The use of local anesthetics provides a novel 
therapeutic approach in the treatment of pain. It is now established that neuraxial 
administration of drugs and use of neurolytic blocks are efficient in reduction of 
intractable cancer pain [88].
The analgesic effect of local anesthetics (procaine, bupivacaine, and lidocaine) 
is enabled by blocking the voltage sensitive Na+ channels, preventing the generation 
and conduction of nerve impulses. It has been also shown that chemical neuromod-
ulation produces effective pain relief. For this purpose, intrathecally can be admin-
istered as local anesthetic, opioids, and adjuvant medications (alpha-adrenergic 
agonists, eg, clonidine), baclofen, and ziconotide. Baclofen is a GABA-B agonist 
who intrathecally inhibits both monosynaptic and postsynaptic reflexes at the spi-
nal level producing muscle relaxation useful in some neuropathic pain syndromes 
[89]. Neuroaxial blocks as the epidural/intrathecal application of opioids (in 
low-dose) and non-opioids drugs (low concentration local anesthetic 0.125–0.25% 
levo-bupivacaine) increases the analgesic effects with few side effects [90].
Also, directly to the area of pain intrathecal pumps for small doses of medica-
tion can be used. The peripheral nerve blocks techniques, catheterization, and 
tumor infiltration prevent and reduce the bad memories of pain. The quality, 
duration, and safety of epidurally applied opioids have been intensively studied 
and compared [91]. It was suggested that sufentanil is a drug with the most promis-
ing profile [92]. Agents may be delivered via variety of catheters and ports. The 
implantation of a self-contained pump delivers medication at a specific rate into the 
subarachnoid space by a subcutaneously tunneled intrathecal catheter.
Neurolytic blocks or neurolysis of peripheral nerves or plexuses (celiac plexus or 
superior hypogastric plexus blocks), with phenol or alcohol, can be used for treat-
ment of neoplasm pain, refractory to pharmacological treatment [93].
6. Non-pharmacological therapy
In recent years, due to the advancement of medical techniques and technol-
ogy, other forms of treatment such as vertebroplasty, spinal cord stimulation, and 
prolo therapy are being used. The integration of the use of interventional medical 
and rehabilitative techniques improves the patients’ lifestyle and helps reduce the 
pain. The use of surgical procedures is very rare for treatment of pain. There are 
some cases where surgery was used for relieving a nerve from compression, or at 
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the disseminated metastatic cancer, a kyphoplasty was used at painful vertebral 
compression fractures [94].
The other alternative forms of nonpharmacological therapy such as chiropractic 
therapy, acupuncture, music, movement therapies or yoga in integration with the 
standard analgesic techniques also provide effective pain relief [95].
Transcutaneous electrical nerve stimulation (TENS) therapy involves the use 
of low-voltage electric currents to treat pain. This small device delivers the current 
at or near nerves producing electro-neuromodulation. It is widely used for treat-
ment of intractable neuropathic and central pain but not for cancer pain and is 
advised in PC [96].
In CONCLUSION, pain management is an especially important part of 
improving the quality of life in terminal patients. Because of the complexity of 
pain, the treatment must be multidisciplinary. Aggregation of PC with other 
settings, the use of MMA, could only permit better prevention of suffering at 
the end of the life. In the conclusion the next message will be greatly beneficial: 
undertreated or untreated pain at the end of the life may be cause patients’ 
discomfort, stress, and suffering, which is a message to the clinicians to increase 
their awareness for pain control during the terminal phase of the life with a liberal 
use of opioids and non-opioids.
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